JP2006511505A - エピガロカテキンガレートおよびラズベリーケトンを含む新規なニュートラシューティカル組成物 - Google Patents
エピガロカテキンガレートおよびラズベリーケトンを含む新規なニュートラシューティカル組成物 Download PDFInfo
- Publication number
- JP2006511505A JP2006511505A JP2004554394A JP2004554394A JP2006511505A JP 2006511505 A JP2006511505 A JP 2006511505A JP 2004554394 A JP2004554394 A JP 2004554394A JP 2004554394 A JP2004554394 A JP 2004554394A JP 2006511505 A JP2006511505 A JP 2006511505A
- Authority
- JP
- Japan
- Prior art keywords
- egcg
- obesity
- composition
- treatment
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 title claims abstract description 74
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 title claims abstract description 74
- 229940030275 epigallocatechin gallate Drugs 0.000 title claims abstract description 74
- VWMVAQHMFFZQGD-UHFFFAOYSA-N p-Hydroxybenzyl acetone Natural products CC(=O)CC1=CC=C(O)C=C1 VWMVAQHMFFZQGD-UHFFFAOYSA-N 0.000 title claims abstract description 70
- NJGBTKGETPDVIK-UHFFFAOYSA-N raspberry ketone Chemical compound CC(=O)CCC1=CC=C(O)C=C1 NJGBTKGETPDVIK-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 239000002417 nutraceutical Substances 0.000 title claims description 13
- 235000021436 nutraceutical agent Nutrition 0.000 title claims description 13
- 208000008589 Obesity Diseases 0.000 claims abstract description 37
- 235000020824 obesity Nutrition 0.000 claims abstract description 37
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 235000013361 beverage Nutrition 0.000 claims abstract description 10
- 235000013305 food Nutrition 0.000 claims abstract description 9
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 239000013589 supplement Substances 0.000 claims abstract description 4
- 230000037396 body weight Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 11
- 239000007787 solid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 235000016709 nutrition Nutrition 0.000 abstract description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- 239000004615 ingredient Substances 0.000 description 18
- 239000004480 active ingredient Substances 0.000 description 16
- 235000019197 fats Nutrition 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 235000005911 diet Nutrition 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000000796 flavoring agent Substances 0.000 description 11
- 235000019634 flavors Nutrition 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 238000011284 combination treatment Methods 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 230000037213 diet Effects 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 239000006188 syrup Substances 0.000 description 7
- 230000004580 weight loss Effects 0.000 description 7
- 206010033307 Overweight Diseases 0.000 description 6
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 6
- 235000005487 catechin Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000004898 kneading Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000003381 stabilizer Substances 0.000 description 6
- 239000003086 colorant Substances 0.000 description 5
- 238000009097 single-agent therapy Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 244000269722 Thea sinensis Species 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- 235000008429 bread Nutrition 0.000 description 4
- 239000001913 cellulose Chemical class 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Chemical class 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013312 flour Nutrition 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 235000015243 ice cream Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000014214 soft drink Nutrition 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000011034 Rubus glaucus Nutrition 0.000 description 3
- 244000235659 Rubus idaeus Species 0.000 description 3
- 235000009122 Rubus idaeus Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 150000001765 catechin Chemical class 0.000 description 3
- 229950001002 cianidanol Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000014594 pastries Nutrition 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 235000021559 Fruit Juice Concentrate Nutrition 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 230000002301 combined effect Effects 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003631 expected effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000008939 whole milk Nutrition 0.000 description 2
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- WQNHWIYLCRZRLR-UHFFFAOYSA-N 2-(3-hydroxy-2,5-dioxooxolan-3-yl)acetic acid Chemical compound OC(=O)CC1(O)CC(=O)OC1=O WQNHWIYLCRZRLR-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 229940127470 Lipase Inhibitors Drugs 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010054805 Macroangiopathy Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010028836 Neck pain Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229910004298 SiO 2 Inorganic materials 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041969 Steatorrhoea Diseases 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000001906 cholesterol absorption Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000021019 cranberries Nutrition 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 229960004597 dexfenfluramine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 229960001582 fenfluramine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 235000021579 juice concentrates Nutrition 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000001022 morbid obesity Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/42—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A21—BAKING; EDIBLE DOUGHS
- A21D—TREATMENT, e.g. PRESERVATION, OF FLOUR OR DOUGH, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS; PRESERVATION THEREOF
- A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1307—Milk products or derivatives; Fruit or vegetable juices; Sugars, sugar alcohols, sweeteners; Oligosaccharides; Organic acids or salts thereof or acidifying agents; Flavours, dyes or pigments; Inert or aerosol gases; Carbonation methods
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
- A23G9/32—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds
- A23G9/36—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G9/366—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing vitamins, antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/56—Flavouring or bittering agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/12—Natural spices, flavouring agents or condiments; Extracts thereof from fruit, e.g. essential oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Confectionery (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
次の実施例で本発明をさらに説明する。
軟ゼラチンカプセル剤
軟ゼラチンカプセル剤を、以下に特定された成分を使用して従来の手順によって調製できる。
エピガロカテキンガレート(EGCG) 100mg
ラズベリーケトン(RK) 100mg
その他の成分:グリセリン、水、ゼラチン、植物油
硬ゼラチンカプセル剤
硬ゼラチンカプセル剤を、以下に特定された成分を使用して従来の手順によって調製できる。
エピガロカテキンガレート(EGCG) 100mg
ラズベリーケトン(RK) 100mg
その他の成分:
充填剤:乳糖またはセルロースまたはセルロース誘導体 適量
滑沢剤:必要なら、ステアリン酸マグネシウム(0.5%)
錠剤
錠剤を、以下に特定された成分を使用して従来の手順によって調製できる。
エピガロカテキンガレート(EGCG) 50mg
ラズベリーケトン(RK) 50mg
その他の成分:微結晶セルロース、二酸化ケイ素(SiO2)、ステアリン酸マグネシウム、クロスカルメロースナトリウム
30%ジュース入り清涼飲料
典型的な1人分: 240ml
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
[g]
1.1 オレンジ濃縮物
ブリックス度60.3°、酸性度5.15% 657.99
レモン濃縮物
ブリックス度43.5°、酸性度32.7% 95.96
オレンジフレーバー、水溶性 13.43
杏子フレーバー、水溶性 6.71
水 26.46
1.2 着色料
10%CWS β−カロテン 0.89
水 67.65
1.3 酸および抗酸化剤
アスコルビン酸 4.11
無水クエン酸 0.69
水 43.18
1.4 安定剤
ペクチン 0.20
安息香酸ナトリウム 2.74
水 65.60
1.5 油溶性フレーバー
油溶性オレンジフレーバー 0.34
留出されたオレンジオイル 0.34
1.6 活性成分
上記の濃度の活性成分EGCGおよびRK
[g]
清涼飲料調合品 74.50
水 50.00
ブリックス度60°砂糖シロップ 150.00
安息香酸ナトリウムを使用する代わりに飲料を低温殺菌してもよい。またその飲料に炭酸ガスを含ませてもよい。
5穀物パン
典型的な1人分 50g
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
その他成分:
[%]
5穀物粉 56.8
水 39.8
酵母 2.3
食塩 1.1
混練:
スパイラル混練システム ファーストギアで4分、セカンドギアで5分
生地プルーフィング 60分
生地温度 22〜24℃
プルーフィング時間 30分
ベーキング:
オーブン オランダ型オーブン
ベーキング温度 250/220℃
ベーキング時間 50〜60分
ミラノ型クッキー
典型的な1人分 30g
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
その他成分: [g]
小麦粉、タイプ550 41.0
砂糖 20.5
脂肪/バター 20.5
全卵(液状) 18.0
レモンフレーバー 適量
ベーキング剤 適量
オーブン:ファンオーブン
ベーキング温度: 180℃
ベーキング時間: 15分
トースト
典型的な1人分 100g
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
その他成分: [%]
小麦粉、タイプ550 55.4
水 33.2
酵母 2.8
食塩 1.1
脂肪/バター 5.5
麦芽 0.6
乳化剤ベーキング剤 1.4
混練:
スパイラル混練システム ファーストギアで5〜6分
セカンドギアで3〜4分
生地プルーフィング なし
生地温度 22〜24℃
プルーフィング時間 40分
ベーキング:
オーブン オランダ型オーブン
ベーキング温度 220℃
ベーキング時間 35〜40分
ヨーグルト−セット型;脂肪3.5%
典型的な1人分 225g
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
その他の成分 [%]
全脂乳(脂肪3.8%) 90.5
脱脂粉乳 2.0
砂糖 5.0
培養菌 2.5
ヨーグルト−攪拌型;脂肪3.5%
典型的な1人分 225g
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
その他成分: [%]
全脂乳(脂肪3.8%) 90.2
脱脂粉乳 2.0
安定化剤 0.3
砂糖 5.0
培養菌 2.5
アイスクリーム;脂肪8%
典型的な1人分 85g
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/1人分
ラズベリーケトン(RK) 0.3〜1250mg/1人分
その他成分: [g]
乳(脂肪3.7%) 600.00
クリーム(脂肪35%) 166.00
脱脂粉乳 49.10
砂糖 109.00
グルコースシロップ80% 70.00
アイスクリーム安定化剤 5.00
フレーバー 適量
着色料 適量
ワインガム
活性成分:
エピガロカテキンガレート(EGCG) 0.3〜1250mg/30g当たり
ラズベリーケトン(RK) 0.3〜1250mg/30g当たり
その他成分: [g]
ゼラチン200ブルーム 80.0
水I 125.0
砂糖結晶 290.0
水II 120.0
グルコースシロップDE38 390.0
クエン酸 10.0
フレーバー 2.0
着色料 適量
計算収量 1000.0
高脂肪、高ショ糖食を食べさせているC57BL6/Jマウス(n=8〜11/グループ)での4週間研究において、体重および脂肪過多症へのEGCGとRKとの併用の有効性を、両方の化合物の単独の有効性と一緒に試験した。食物誘発性肥満および早期II型糖尿病のこのモデルは、抗肥満化合物の有効性を決定するのに広く使用されている。
C57BLKS/J db/dbマウス(n=8〜9/グループ)での5週間研究において、体重および脂肪過多症へのEGCGとRKとの併用の有効性を、両方の化合物の単独の有効性と一緒に試験した。重篤な高血糖症および肥満症を有する後期II型糖尿病のこのモデルは、抗糖尿性および抗肥満性化合物の有効性を決定するのに広く使用されている。
Claims (10)
- 有効量のエピガロカテキンガレート(EGCG)と4−(4−ヒドロキシフェニル)−2−ブタノン(RK)とを含むニュートラシューティカル組成物。
- 肥満または肥満に関連する状態、例えば非インシュリン依存性糖尿病(NIDDM、II型)および症候群Xの治療または予防用の請求項1に記載の組成物。
- 体重kgにつき約0.01〜約60mgのEGCGを対象に投与するに十分な量のEGCGと、体重kgにつき約0.01〜約60mgのRKを対象に投与するに十分な量のRKとを含む請求項1または2に記載の組成物。
- 医薬組成物である請求項1から3のいずれか一つに記載の組成物。
- 投与単位中に約10〜約500mgのEGCGと約10〜約500mgのRKとを含む固形医薬組成物である請求項4に記載の組成物。
- 投与単位中に約10〜約50mgのEGCGと約10〜約50mgのRKとを含む固形医薬組成物である請求項4に記載の組成物。
- 食品または飲料あるいは食品または飲料用のサプリメント組成物である請求項1から3のいずれか一つに記載の組成物。
- 肥満または肥満に関連する状態、例えば非インシュリン依存性糖尿病(NIDDM、II型)および症候群Xの治療または予防用のニュートラシューティカル組成物の製造におけるEGCGおよびRKの使用。
- EGCGが、投与されるべき対象の体重kgにつき約0.01〜約60mgの1日の投与量を供給するのに十分な量で使用され、そしてRKが、投与されるべき対象の体重kgにつき約0.01〜約60mgの1日の投与量を供給するのに十分な量で使用される請求項8に記載の使用。
- 肥満または肥満に関連する状態、例えば非インシュリン依存性糖尿病(NIDDM、II型)および症候群Xの治療または予防の方法であって、そのような処置が必要な対象に有効量のEGCGとRKとの組み合わせを投与することを含む方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02026575 | 2002-11-28 | ||
EP02026575.7 | 2002-11-28 | ||
PCT/EP2003/012975 WO2004047926A1 (en) | 2002-11-28 | 2003-11-20 | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006511505A true JP2006511505A (ja) | 2006-04-06 |
JP4708031B2 JP4708031B2 (ja) | 2011-06-22 |
Family
ID=32338005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004554394A Expired - Fee Related JP4708031B2 (ja) | 2002-11-28 | 2003-11-20 | エピガロカテキンガレートおよびラズベリーケトンを含む新規なニュートラシューティカル組成物 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20050288360A1 (ja) |
EP (1) | EP1575671B1 (ja) |
JP (1) | JP4708031B2 (ja) |
KR (1) | KR20050071709A (ja) |
CN (1) | CN1717268B (ja) |
AT (1) | ATE541616T1 (ja) |
BR (1) | BR0316681A (ja) |
CO (1) | CO5690572A2 (ja) |
ES (1) | ES2380825T3 (ja) |
MX (1) | MXPA05005479A (ja) |
NZ (1) | NZ540258A (ja) |
RU (1) | RU2340337C2 (ja) |
TR (1) | TR200501978T2 (ja) |
WO (1) | WO2004047926A1 (ja) |
ZA (1) | ZA200504180B (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007112996A2 (en) * | 2006-03-31 | 2007-10-11 | Dsm Ip Assets B.V. | Novel use of compounds and combinations of compunds for improving the physical appearance |
CA2714374A1 (en) * | 2009-09-02 | 2011-03-02 | Nuvocare Health Sciences Inc. | Weight loss composition and method |
FR2956290B1 (fr) * | 2010-02-16 | 2013-01-11 | Michel Marcel Andre Loiselet | Procede et installation de transformation d'une substance pateuse en produit fini alimentaire ainsi qu'atelier de transformation |
EP2460413A1 (en) * | 2010-12-01 | 2012-06-06 | Nestec S.A. | Set-style fruit yoghurts |
KR102414148B1 (ko) * | 2019-11-18 | 2022-06-28 | 이동수 | 복분자 계란의 생산 방법 및 상기 방법으로 생산된 복분자 계란 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847698A1 (de) * | 1996-12-12 | 1998-06-17 | KRÜGER GmbH & CO. KG | Zubereitungsfertig verpacktes Instant-Teeprodukt und Verfahren zu seiner Herstellung |
JP2000169325A (ja) * | 1998-12-11 | 2000-06-20 | Kanebo Ltd | 脂肪分解促進剤及び痩身用皮膚化粧料 |
WO2002072086A2 (en) * | 2001-03-12 | 2002-09-19 | Consorzio Per Gli Studi Universitari | Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases |
US20050113426A1 (en) * | 2000-02-18 | 2005-05-26 | Shutsung Liao | Polyhydroxylated benzene-containing compounds |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6299925B1 (en) * | 1999-06-29 | 2001-10-09 | Xel Herbaceuticals, Inc. | Effervescent green tea extract formulation |
-
2003
- 2003-11-20 RU RU2005120154/15A patent/RU2340337C2/ru not_active IP Right Cessation
- 2003-11-20 MX MXPA05005479A patent/MXPA05005479A/es active IP Right Grant
- 2003-11-20 EP EP03767578A patent/EP1575671B1/en not_active Expired - Lifetime
- 2003-11-20 AT AT03767578T patent/ATE541616T1/de active
- 2003-11-20 ES ES03767578T patent/ES2380825T3/es not_active Expired - Lifetime
- 2003-11-20 NZ NZ540258A patent/NZ540258A/en unknown
- 2003-11-20 WO PCT/EP2003/012975 patent/WO2004047926A1/en active Application Filing
- 2003-11-20 CN CN2003801045940A patent/CN1717268B/zh not_active Expired - Fee Related
- 2003-11-20 KR KR1020057009507A patent/KR20050071709A/ko active IP Right Grant
- 2003-11-20 TR TR2005/01978T patent/TR200501978T2/xx unknown
- 2003-11-20 US US10/536,374 patent/US20050288360A1/en not_active Abandoned
- 2003-11-20 JP JP2004554394A patent/JP4708031B2/ja not_active Expired - Fee Related
- 2003-11-20 BR BR0316681-3A patent/BR0316681A/pt not_active IP Right Cessation
-
2005
- 2005-05-23 ZA ZA200504180A patent/ZA200504180B/en unknown
- 2005-06-28 CO CO05063331A patent/CO5690572A2/es not_active Application Discontinuation
-
2009
- 2009-05-04 US US12/387,639 patent/US20090221694A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0847698A1 (de) * | 1996-12-12 | 1998-06-17 | KRÜGER GmbH & CO. KG | Zubereitungsfertig verpacktes Instant-Teeprodukt und Verfahren zu seiner Herstellung |
JP2000169325A (ja) * | 1998-12-11 | 2000-06-20 | Kanebo Ltd | 脂肪分解促進剤及び痩身用皮膚化粧料 |
US20050113426A1 (en) * | 2000-02-18 | 2005-05-26 | Shutsung Liao | Polyhydroxylated benzene-containing compounds |
WO2002072086A2 (en) * | 2001-03-12 | 2002-09-19 | Consorzio Per Gli Studi Universitari | Use of epigallocatechin-3-gallate or its derivatives in the prevention and treatment of neurodegenerative diseases |
Non-Patent Citations (1)
Title |
---|
JPN6010018023, Herve Casabianca et. al., "Enantiomeric and isotopic analysis of flavour compounds of some raspberry cultivars", Journal of Chromatography A, 1994, Volume 684, Issue 2, p.360−365 * |
Also Published As
Publication number | Publication date |
---|---|
CO5690572A2 (es) | 2006-10-31 |
CN1717268B (zh) | 2011-03-23 |
RU2005120154A (ru) | 2006-01-27 |
WO2004047926A1 (en) | 2004-06-10 |
TR200501978T2 (tr) | 2005-09-21 |
BR0316681A (pt) | 2005-10-18 |
ATE541616T1 (de) | 2012-02-15 |
RU2340337C2 (ru) | 2008-12-10 |
EP1575671A1 (en) | 2005-09-21 |
NZ540258A (en) | 2007-01-26 |
US20050288360A1 (en) | 2005-12-29 |
US20090221694A1 (en) | 2009-09-03 |
KR20050071709A (ko) | 2005-07-07 |
EP1575671B1 (en) | 2012-01-18 |
MXPA05005479A (es) | 2005-07-25 |
ES2380825T3 (es) | 2012-05-18 |
ZA200504180B (en) | 2006-02-22 |
JP4708031B2 (ja) | 2011-06-22 |
CN1717268A (zh) | 2006-01-04 |
AU2003292049A1 (en) | 2004-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070036873A1 (en) | Method of treatment or management of stress | |
US20180104299A1 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a satiation agent for the treatment of obesity | |
KR101692033B1 (ko) | D-싸이코스를 유효성분으로 함유하는 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
EP2138055B2 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
US20060165671A1 (en) | Novel nutraceutical compositions comprising epigallocatechin gallate | |
US20050256178A1 (en) | Novel nutraceutical compositions comprising boitin | |
JP2014114303A (ja) | 組成物 | |
US20090221694A1 (en) | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone | |
CN100518733C (zh) | 用于治疗和预防糖尿病的组合物 | |
US6210702B1 (en) | Weight loss composition and method for losing weight | |
JP2008143811A (ja) | 脂質代謝促進組成物 | |
JP2002308766A (ja) | 生活習慣病予防・改善剤 | |
AU2003292049B2 (en) | Nutraceutical compositions comprising epigallocatechin gallate and raspberry ketone | |
JP2001335491A (ja) | 高脂血症の予防又は治療剤 | |
EA011008B1 (ru) | Способ получения пюре из плодов папайи, применение пюре и препарат | |
KR20210029462A (ko) | 혈류 개선용 건강기능식품 조성물 및 이의 제조 방법 | |
WO2010119804A1 (ja) | 抗精神疲労剤 | |
US7348033B1 (en) | Cold-remedy food supplement for simultaneously lowering blood pressure and sustaining blood sugar | |
TW202408561A (zh) | 眼血流之改善以及/或是維持用組成物、眼部之血管組織之健全性維持用組成物、眼部之抗老化用組成物、針對眼部之健全性、視野狹窄、視野缺損、或是暗點之出現或擴大之改善以及/或是維持用組成物、眼循環障礙之治療以及/或是預防用組成物 | |
CN113519729A (zh) | 山楂饮料及其制备方法 | |
JP2019196330A (ja) | 糖質吸収抑制剤 | |
Dare et al. | An evaluation study to assess the potential use of Renamil (formerly named Ren‐o‐mil) for patients with chronic renal failure | |
JP2010248141A (ja) | 肝機能改善剤 | |
JP2018064492A (ja) | たんぱく質効率向上用の組成物 | |
MX2008001176A (es) | Método para tratamiento o manejo del estrés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061003 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20061130 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20061208 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100413 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100713 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100721 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100813 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110316 |
|
LAPS | Cancellation because of no payment of annual fees |